Amarin Corporation (NASDAQ: AMRN) Stock Trading Halted Today; FDA Advisory Committee to Review sNDA for Vascepa(R) ANCHOR Indication
October 16, 2013 04:10 ET
|
Amarin Corporation plc
BEDMINSTER, N.J., and DUBLIN, Ireland, Oct. 16, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of...
Amarin to Host Conference Call on October 16, 2013 to Discuss Results of FDA Advisory Committee Meeting on ANCHOR Supplemental New Drug Application (sNDA) for Vascepa(R)
October 09, 2013 08:30 ET
|
Amarin Corporation plc
Approval of the ANCHOR sNDA Would Expand Use of Vascepa to Include the Treatment of Patients with High Triglycerides (≥200 mg/dL and <500 mg/dL) with Mixed Dyslipidemia
BEDMINSTER, N.J.,...
Amarin Informed by FDA That October 16th Advisory Committee Meeting Will Take Place as Scheduled
October 03, 2013 08:15 ET
|
Amarin Corporation plc
BEDMINSTER, N.J. and DUBLIN, Ireland, Oct. 3, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of...
Amarin Announces Enrollment of the REDUCE-IT Cardiovascular Outcomes Study Surpasses 6,000 Patients
September 25, 2013 06:00 ET
|
Amarin Corporation plc
BEDMINSTER, N.J., and DUBLIN, Ireland, Sept. 25, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of...
Amarin to Present at the 2013 Aegis Capital Healthcare Conference
September 18, 2013 06:10 ET
|
Amarin Corporation plc
BEDMINSTER, N.J. and DUBLIN, Ireland, Sept. 18, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of...
Amarin Announces 30th Patent for Vascepa(R)
September 09, 2013 07:18 ET
|
Amarin Corporation plc
BEDMINSTER, N.J., and DUBLIN, Sept. 9, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to...
Amarin Announces Submission of Supplemental New Drug Application for Novasep as Fourth Vascepa(R) Active Pharmaceutical Ingredient Supplier
August 26, 2013 06:00 ET
|
Amarin Corporation plc
BEDMINSTER, N.J. and DUBLIN, Ireland, Aug. 26, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of...
Amarin to Present at the Canaccord Genuity 33rd Annual Growth Conference
August 13, 2013 06:00 ET
|
Amarin Corporation plc
BEDMINSTER, N.J. and DUBLIN, Ireland, Aug. 13, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of...
Amarin Reports Second Quarter 2013 Financial Results and Provides Update on Operations
August 08, 2013 16:02 ET
|
Amarin Corporation plc
BEDMINSTER, N.J. and DUBLIN, Ireland, Aug. 8, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company focused on the commercialization and development of...
Amarin to Report Second Quarter 2013 Results and Host Conference Call on August 8, 2013
August 02, 2013 16:05 ET
|
Amarin Corporation plc
BEDMINSTER, N.J. and DUBLIN, Ireland, Aug. 2, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of...